Alnylam Pharmaceuticals (NASDAQ: ALNY) is lower off the open after Nomura/Instinet analyst Christopher Marai said the FDA's Center for Drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE